| Literature DB >> 24052816 |
Dina A Bakhotmah1, Reda M Abdul-Rahman, Mohammad S Makki, Mohamed A El-Zahabi, Mansor Suliman.
Abstract
The emerging resistance to antimicrobial drugs demands the synthesis of new remedies for microbial infections. Attempts have been made to prepare new compounds by modifications in theEntities:
Year: 2011 PMID: 24052816 PMCID: PMC3767343 DOI: 10.5402/2011/184754
Source DB: PubMed Journal: ISRN Org Chem ISSN: 2090-5149
Scheme 1Norfloxacin modification.
Scheme 2
Scheme 3
Figure 3TG and TGD for compound 12.
Figure 4Suggested decomposition stages for compound 12.
Scheme 4A possible formation of N, N′-bis-Aryl malonamide instead of norfloxacin analogues.
Scheme 5
Figure 2The interaction between compound 12 with CHCl3.
Figure 1FT-IR spectrum of 12 in (a) solid and (b) solution states for compound 12.
Various physicochemical properties of highly bioactive compounds.
| Compd. No. | MIC at 30 | Mol. Mass | Melting point | Solubilityc in water (20°C), | ||||
|
|
|
|
| CHCl3 a | Cyclo-Hexaneb | |||
|
| ||||||||
|
| 6 | 10 | 10 | 8 | 299 | 90 | 87 | 200 |
|
| 6 | 10 | 10 | 9 | 327 | 191 | 186 | 300 |
|
| 6 | 10 | 6 | 10 | 374 | 74 | 70 | 90 |
|
| 6 | 10 | 6 | 9 | 366 | 111 | 107 | 350 |
|
| 15 | 10 | 12 | 12 | 442 | 285 | — | 400 |
| Ny | 6 | 6 | 6 | 6 | — | — | — | — |
| Na | 32 | 30 | 30 | 32 | — | — | — | — |
aCrystals cyclisation from CHCl3; bCrystals cyclisation from cyclohexane; chydrolysis characteristics at pH 5.7 and 9 and at 24°C. The tested compounds have a very low rate of hydrolysis, which is considered stable in suspension concentrations under normal condition.
The preliminary screening of antimicrobial activity of the new synthesized compounds.
| Compounds/DMF 50 | Microorganisms/Inhibition zone (mm) | |||||
|---|---|---|---|---|---|---|
| Gram +ve bacteriaa | Gram − ve bacteriab | Fungic | ||||
|
|
|
|
|
| A.F. | |
|
| 9 | 8 | 8 | 10 | 10 | 6 |
|
| 18 | 16 | 15 | 14 | 10 | 6 |
|
| 16 | 16 | 14 | 14 | 8 | 6 |
|
| 8 | 8 | 7 | 11 | 9 | 6 |
|
| 13 | 11 | 12 | 13 | 9 | 6 |
|
| 15 | 14 | 15 | 13 | 10 | 6 |
|
| 20 | 19 | 18 | 17 | 10 | 10 |
| Ny. | 6 | 6 | 6 | 10 | 10 | 32 |
| Na. | 32 | 30 | 30 | 22 | 6 | 6 |
Ny: nystatin, manufactured by Pasteur Lab., Egypt. NS 100 units (100 μg/disk).
Na: nalidixic acid, 30 μg/disk, Bioanalize, Egypt.
a Bacillus Subtilis (B.S.) and Stphylacoccus Aureus (S.A.); b Escherichia Coli (E.C.) and Klebsiella Pneumonia (K.P.); c Candida Albicans (C.A.) and Aspergillus Funigates (A.F.).
MIC of the active biological compounds towards bacteria.
| Compd. No. | Inhibition Zones ( | |||||||||||
|
|
|
|
| |||||||||
| 50 | 40 | 30 | 50 | 40 | 30 | 50 | 40 | 30 | 50 | 40 | 30 | |
|
| ||||||||||||
|
| 18 | 12 | 6 | 16 | 14 | 10 | 15 | 12 | 10 | 14 | 12 | 8 |
|
| 16 | 14 | 6 | 16 | 12 | 10 | 14 | 13 | 10 | 14 | 11 | 9 |
|
| 13 | 10 | 6 | 11 | 10 | 10 | 12 | 10 | 6 | 13 | 11 | 10 |
|
| 15 | 12 | 6 | 14 | 12 | 10 | 15 | 12 | 6 | 13 | 11 | 9 |
|
| 20 | 18 | 15 | 19 | 16 | 10 | 18 | 16 | 12 | 17 | 14 | 12 |
Preliminary screening using UV (λ366 nm) light, conc. 50 μg/disk.
| Compd. No. | Microorganisms (inhibition zones in mm) | |||||
| +ve bacteria | − ve bacteria | Fungi | ||||
|
|
|
|
|
| A.F. | |
|
| ||||||
|
| 18 | 16 | 15 | 14 | No change | No change |
|
| 18 | 17 | 16 | 18 | No change | No change |
|
| 14 | 14 | 12 | 14 | No change | No change |
|
| 17 | 16 | 17 | 16 | No change | No change |
|
| 24 | 21 | 21 | 21 | No change | No change |